Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:
“Today I had the opportunity to speak at the DAVA Oncology Translational Summit on Hematologic Malignancies about the innovation that Johnson and Johnson Innovative Medicine is leading.
What continues to energize me is the pace of scientific progress and the collective commitment across our community to improve outcomes for patients. At Johnson and Johnson, our ambition is bold: to lead the next wave of oncology innovation and help transform cancer care through breakthrough science, strong partnerships, and a relentless focus on patients.
The future will be shaped by our ability to translate innovation into meaningful impact for patients and their families. That requires collaboration across researchers, clinicians, patient advocates, and industry, all united by a common purpose.
Thank you to DAVA Oncology for bringing together such an outstanding group of leaders dedicated to advancing the future of cancer care and in particular Vinay Jain.
‘Our responsibility is not just to advance medicines, but to advance hope for patients by turning scientific possibilities into clinical reality’.”
Other articles featuring Mark Wildgust on OncoDaily.
